Related references
Note: Only part of the references are listed.Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma
Christine Elser et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Multicenter phase II study of combined neoadjuvant docetaxel and androgen ablation (ADT) prior to radical prostatectomy (RP) for patients (pts) with high risk localized prostate cancer (LCaP): Pathologic outcomes and 3-year follow-up analyses
E. Winquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
What is the most cost-effective population-based cancer screening program for Chinese women?
Pauline P. S. Woo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay?
Francoise Dignat-George et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Improving the design of phase II trials of cytostatic anticancer agents
Andrew Stone et al.
CONTEMPORARY CLINICAL TRIALS (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The ability of sorafenib to inhibit oncogenic PDGFR beta and FLT3 mutants and overcome resistance to other small molecule inhibitors
Els Lierman et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Global trends in breast cancer incidence and mortality 1973-1997
MD Althuis et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2005)
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
MA Cobleigh et al.
SEMINARS IN ONCOLOGY (2003)
Share Paper
